Diagreat has been continuously developing and innovating in order to improve the precise drug use of patients and contributing its own strength to protect the health of the people. To meet the needs of customers and the market, Diagreat has achieved a breakthrough in the detection of small molecule and large molecule drugs on the same platform. At present, more than 30 kinds of macromolecule and small molecule drug concentration detection can be carried out.

Diagreat innovatively adopts chemiluminescence detection technology to realize the detection of small molecules and macromolecular drugs on the same platform. Its fully automatic chemiluminescence immune system realizes high-throughput and fully automated detection, with unattended, full-process quality control, and stable results and other advantages. It provides comprehensive and complete professional testing services for clinical drug use and precise diagnosis and treatment, and protects the safety of drug use for patients.

At the same time, Diagreat also provides long-difficult gene synthesis services, customized probe synthesis services, other key scientific research services, nucleic acid molecular detection raw materials and other advantageous scientific research service products.